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Abstract
We present a new approach to the study of the immune system that combines techniques of systems biology with
information provided by data-driven prediction methods. To this end, we have extended an agent-based simulator of the
immune response, C-IMMSIM, such that it represents pathogens, as well as lymphocytes receptors, by means of their amino
acid sequences and makes use of bioinformatics methods for T and B cell epitope prediction. This is a key step for the
simulation of the immune response, because it determines immunogenicity. The binding of the epitope, which is the
immunogenic part of an invading pathogen, together with activation and cooperation from T helper cells, is required to
trigger an immune response in the affected host. To determine a pathogen’s epitopes, we use existing prediction methods.
In addition, we propose a novel method, which uses Miyazawa and Jernigan protein–protein potential measurements, for
assessing molecular binding in the context of immune complexes. We benchmark the resulting model by simulating a
classical immunization experiment that reproduces the development of immune memory. We also investigate the role of
major histocompatibility complex (MHC) haplotype heterozygosity and homozygosity with respect to the influenza virus
and show that there is an advantage to heterozygosity. Finally, we investigate the emergence of one or more dominating
clones of lymphocytes in the situation of chronic exposure to the same immunogenic molecule and show that high affinity
clones proliferate more than any other. These results show that the simulator produces dynamics that are stable and
consistent with basic immunological knowledge. We believe that the combination of genomic information and simulation
of the dynamics of the immune system, in one single tool, can offer new perspectives for a better understanding of the
immune system.
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Introduction
The immune system, due to its very complex nature, is one of
the most challenging topics in biology. Its study often relies on in
vivo or in vitro animal models, mathematical models, or computa-
tional (in silico) models. Recent advances in the field of
bioinformatics have provided a number of techniques for
processing and integrating the explosion of data that has been
produced during the rise of genomics, which has also improved our
ability to predict the molecular specificities of the immune system
(for a review see e.g., [1]). A number of mathematical models
based on either differential equations or interacting discrete entities
(agents) have also been proposed to describe various aspects of the
immune system. However, most of the existing simulation-based
approaches resort to oversimplified models of molecular interac-
tions, because detailed quantitative data, needed for a more
realistic representation, were not always available.
The goal of the present work is to present a novel approach for
the study of the immune system, combining a mesoscopic scale
simulator of the immune system [2] with a set of machine learning
techniques for molecular-level predictions of major histocompat-
ibility complex–peptide binding interactions [3–6], linear B cell
epitope discovery, as well as a more general protein–protein
potential estimation [7]. More specifically, the computational
model belongs to an agent-based class, whereas the prediction of
epitopes relies on machine learning techniques, such as Neural
Networks (NN).
The paper is organized as follows: After an introduction to the
fundamental mathematics required for modeling the immune
system, we present results of simulations whose aim is to test the
correctness the new tool. We concludes the paper with a
perspective on the future of this work. Finally, the materials and
methods section describes the bioinformatics tools used for
predicting the interactions among the entities involved in the
immune response, including a description of how they are
incorporated into the mesoscopic C-IMMSIM simulator.
In silico models of the immune system
The immune system can be viewed as a classic system of
coupled components, with birth, death, and interaction elements.
The most common modeling approach utilizes systems of either
Ordinary or Partial Differential Equations (ODE and PDE,
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respectively) that directly describe the evolution of global
quantities or populations over time [8]. In immunology, these
quantities could be, for instance, the total concentration of viral
particles or cell counts. ODE- and PDE-based models enable a
model to use well-established analytical and numerical techniques,
but they potentially oversimplify the system: an entire population
of discrete entities is described by a single continuous variable.
Mathematical models based on differential equations have proved
very useful. The study of the evolution of HIV into AIDS, for
instance, has been modeled with the purpose of predicting the
effects of specific treatments [9–12], and predicting certain aspects
of disease progression [13–23].
Each entity (e.g., a cell) is individually represented by an agent,
and the interactions among agents are defined by a set of rules that
can have stochastic components. The rules reflect the current
knowledge in immunology, but they can also be defined ad hoc to
test new hypotheses regarding the operation of the immune
system.
One of the first attempts to define a detailed agent-based model
of immunological mechanisms was the work of Celada and Seiden
[2,24,25]. Their goal was to capture the dynamics of the immune
system, as much as possible, and to perform experiments in silico.
Along similar lines, a study of the thymus has been carried out
[26]. This approach provided important insights into the
regulation of positive and negative selection and into the dynamics
of the production of the TCR repertoire in the thymus. More
recently, we have developed specialized versions of the Celada-
Seiden model to study HIV-1 infection, EBV infection, hypersen-
sitivity reactions, and cancer immunoprevention (described,
respectively, in [27–30]). Recentely, another implementation of
the same model has been used to study cross reactivity and
heterologous memory [31].
C-IMMSIM, the simulator that implements our version of the
Celada-Seiden model, is a flexible tool that can be used for the study
of a number of different immunological processes. The original
model used bit strings to represent the receptors of biological entities.
Related works
Recently, there has been renewed interest in modeling the
immune system by means of agent-based models.
Simmune [32] aims at being a flexible platform for the
simulation of any immunological process. It is more of a modeling
technique and a language for the description of models than a
specific model. Simmune is based on a particular representation of
particle interactions that can be used to create detailed models of
the immune system. The particles live on a mesh, and their states
are updated at discrete time-steps so that both time and space are
discrete. Particles in Simmune can be in different states.
Transitions among the states are probabilistic events triggered
by the exchange of messenger particles having a limited range. The
messenger field intensities are calculated by the integration of
reaction-diffusion equations and typically include an activation
threshold. A major advantage of Simmune is that it models both
direct intercellular interactions (such as those between an antigen
and a B cell) and interactions mediated by molecular messengers
(such as lymphokines). It also supports spatial compartmentaliza-
tion and communication conduits.
The Basic Immune Simulator (Bis) [33] is an agent-based model
created to study the interactions among the cells of the innate and
adaptive immune systems. Bis simulates basic cell types, mediators,
and antibodies, and consists of three virtual spaces representing
parenchymal tissue, secondary lymphoid tissue, and the lymphat-
ic/humoral circulation. Bis translates mechanistic cellular and
molecular knowledge regarding the innate and adaptive immune
response and reproduces the immune system’s complex behavioral
patterns. It has been used both as an educational tool to
demonstrate the emergence of those patterns and as a research
tool to systematically identify potential targets for more effective
treatment strategies for diseases processes, including hypersensi-
tivity reactions, autoimmunity, and cancer.
Simisys [34] is a cellular automata-based method that allows the
simulation of tens of thousands of cells. Both innate and adaptive
components of the immune system are represented. Specifically,
macrophages, dendritic cells, neutrophils, natural killer cells, B
cells, T helper cells, complement proteins, and pathogenic bacteria
are present in the model.
Bit string models of immune diversity
A fundamental task of the immune system is to recognize and
bind antigens by means of cell receptors. The binding mechanism
is based on physical–chemical processes (short-range non-covalent
interactions, hydrogen bonding, van der Waals interactions) [8].
The features that determine the binding among molecules [35]
may be represented by a shape-space. Under the assumption that the
shape-space can be described by means of K parameters, a point
in this K-dimensional space specifies the generalized shape of a
binding region. Oster and Perelson estimated that in order to be
complete, the receptor repertoire should fulfill the following
conditions: i) each receptor should recognize a set of related
epitopes, each of which differs slightly in shape; ii) the repertoire
size should be on the order of 1016 or larger; iii) at least one subset
of the repertoire should be distributed randomly throughout the
shape-space. Later, Farmer and co-workers [36] introduced the
idea of using binary strings to represent the generalized shape of a
receptor. To determine the degree of affinity between bit-strings, it
is possible to resort to different string-matching criteria. For
instance, by using a key–lock analogy, two binary strings have a
high affinity if they complement each other, that is, when the two
strings are lined up, every ‘‘0’’ in one string corresponds to a ‘‘1’’ in
the other, and conversely. The bit string representation of antigen
and cell receptor diversity was then adopted by a number of other
authors [37–39], and has been the basis for the description of all
molecular interactions in earlier implementations of the Celada-
Seiden model.
Previous version of C-ImmSim
The C-IMMSIM model of the immune system response has been
quite extensively described in [27,40]. C-ImmSim was imple-
mented in ANSI C language. In short, it consists of a three-
dimensional (3D) stochastic cellular automaton in which the major
classes of cells of both the lymphoid (T helper lymphocytes (Th),
cytotoxic T lymphocytes (CTL), B lymphocytes, and antibody-
producer plasma cells, PLB) and the myeloid lineage (macrophag-
es (Mw) and dendritic cells (DC)) are represented. All these entities
interact with each other according to a set of rules that describe
the different phases of the recognition and response processes of
the immune system against a pathogen.
C-IMMSIM can be classified as a bit-string polyclonal lattice
model. Bit-string refers to the way in which the molecules are
represented, polyclonal indicates that the lymphocytes have
genetic variation in their receptors, and lattice signifies that a
discrete lattice is used to represent the space.
The model mainly represents a portion of a tertiary organ such
as a lymph node, tonsil, or spleen. Tertiary organs are sites in
which antigens are presented to immune cells. C-IMMSIM
simultaneously simulates three compartments that represent three
separate anatomical regions found in mammals: (i) the bone
marrow, where hematopoietic stem cells are simulated, which
Computational Bioinformatics
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produce new lymphoid and myeloid cells; (ii) the thymus, where
naı¨ve T cells are selected to avoid auto-reactivity; and (iii) a tertiary
lymphatic organ, such as a lymph node. The tertiary organ is the
only compartment that is described geometrically, because it is
mapped onto a 3D lattice. All interactions among cells and
molecules take place on a lattice-site during each time step. The
diffusion of entities at each time step models the physical spreading
of molecules in the lymphatic organ.
A set of self peptides is used to define the ‘‘self’’ at the beginning
of the simulation. Non-self is defined as everything else. Potential
pathogens as well as cell receptors and MHC molecules (the HLA
or Human Leukocyte Antigen), are represented as binary strings.
In the model, all cells are considered ‘active’ or ‘resting’. This
means that naı¨ve cells are not taken into account. Hence, all cells
reaching the tertiary organ (the simulation space) are already
mature. T-lymphocytes are exceptions, because they undergo
thymic selection before entering circulation. The lymphocytes
generated in the bone marrow have a high diversity with respect to
their receptors, due to alternative splicing, which is somatic
rearrangement of noncontiguous genomic V, J, and C regions,
and sometimes hypermutation. We represent this phenomenon by
assigning random bit-string receptors to every lymphocyte.
C-IMMSIM incorporates the following working hypothesis or
theories: i) the diversity of specific elements [41–43]; ii) antigen
processing and presentation [44–47]; iii) MHC restriction [48]; iv)
cell–cell cooperation [49,50]; v) maturation of the response and
memory [51,52]; vi) clonal selection by antigen affinity ([53]); vii)
thymus education of T lymphocytes (clonal deletion theory, [54]);
viii) hypermutation of antibodies; ix) Hayflick limit (T cell
replicative senescence [55–58]); x) Ag dose-induced tolerance
(anergy) in B cells [59,60].
xi) T cell anergy [61];
xii) Matzinger’s danger signals [62];
xiii) Idiotypic Network theory [63]. Further information can be
found in the literature.
Results
In the remainder of this section, we describe some numerical
experiments that were designed with the goal of assessing the
soundness of the simulator. The average execution time was
around three hours on a 2.4 GHz Opteron processor. In terms of
memory consumption, the simulation of a 10 microliter volume
requires 1 GB of RAM.
Immunization experiment
In this experiment, we reproduce the typical immunization
process by injecting an immunogenic protein at two subsequent
instants in time. The actual AA string used as an antigenic
molecule is the gag molecule from HIV-1.
The antigen is injected at time zero, then again six months (of
simulated time) later. The system develops a typical primary and
secondary immune response with a significant increase in memory
lymphocytes, as shown in Figure 1. Panel (a) and panel (b) show,
respectively, the cell counts of B and T helper lymphocytes in a
cubic millimeter. The immunological memory is developed during
the first response. Therefore, the second response is much more
rapid, as can be seen in the inset plot of panel (c), which shows the
time the immune system takes to clear the antigen. The same
panel also shows the humoral response in terms of antibody titers
(arbitrary scale). In summary, the dynamics are consistent with a
realistic immunization process, because they show a faster
secondary response due to the development of long-lasting
memory.
Immunodominance or affinity maturation
In this experiment, we test the emergence of one or more
dominating clones of lymphocytes in the situation of chronic
exposure to the same immunogenic molecule. In other words, we
check if the system reproduces the phenomenon of affinity
maturation. To mimic chronic exposure to a pathogen, we
repeatedly inject a certain amount of the HIV/gag protein (for
example) throughout the simulation period.
The system responds by mounting a specific immune response
from the beginning of exposure. Then, as the simulation proceeds,
higher affinity clones overtake the original clones with respect to
expression levels, eventually proliferating at higher levels than any
other. This is shown in Figure 2, in which the lymphocyte T helper
count for the top-ranked clones is shown alongside the specific
TCRs. Note, in particular, that the dashed line corresponds to the
first emerging clone, and the continuous line shows a later-
appearing clone with a better affinity that overcomes the first
clone. In the inset plot of the same figure, we show the Simpson
index D~
P
i (ni=N)
2, where N~
P
i ni and ni is the count of the
clone with specificity i. The increase of the index D over time
indicates the emergence of a dominating clone (i.e., the bigger the
value of D, the lower the diversity).
Homozygote vs heterozygote
There are reasons to believe that the ‘‘time to AIDS’’ in HIV-
infected patients is related to the haplotype homozygosity [64].
Individuals that bear a higher diversity in their MHC have slower
progression to AIDS than those with lower diversity. In the
analysis carried out by Carrington [64], individuals carrying
heterozygosity for HLA-A, HLA-B, or HLA-C each showed a
longer AIDS-free period compared to their homozygote locus
counterparts. Here, we simulate the situation and compare the
time to clear a given antigen (not specifically the HIV-1) for
individuals with full heterozygosity and individuals with homozy-
gosity for their MHC loci. The heterozygote haplotype is a full
heterozygote, meaning that we allow all possible loci to be
different. The homozygotes bear one A- allele, one B- allele, and
one DR- allele. The following set of MHCs have been used,
following the article by Hoof et al., in which MHC alleles are
ranked based on observed viremia levels in HIV-I-infected patients
[65]: homozygote genotype: A0201, B5304, DRB30302;
heterozygote genotype: A0201, A0301, B5304,B5309,
DRB30302,DRB50202.
The antigen used encompassed all proteins from the Flu
influenza A serotype H1N1 (genome id: HU13275) in the flu
genome database (www.flugenome.org). For demonstration pur-
poses, we assume that the virus does not mutate. The results of
simulations, shown in Figure 3, indeed show that the speed of
antigen clearance is faster for simulations with a heterozygote
haplotype. It is also worth noting that the immune effort calculated
as the number of cells (both CTLs and CD4z T-cells) during the
immune response is higher for the homozygote-type, consistent
with the fact that the homozygote immune response is poorer and,
therefore, allows the virus to grow to higher numbers before it is
cleared. The opposite situation holds for the heterozygote immune
system, which optimally clears the virus faster and with less effort.
Discussion
We have presented an integrated multi-level model that
describes the immune system response at the mesoscopic level
and, at the same time, takes into account the recognition
mechanisms among molecules by means of prediction tools based,
in part, on well known techniques for epitope discovery.
Computational Bioinformatics
PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e9862
We have tested the simulator in typical immunization
experiments, in which the immune system develops memory.
We have shown that the system develops affinity maturation
against ‘‘chronic’’ antigenic peptides, and we have also shown that
heterozygosity helps the immune system to cope with the diversity
of pathogens. These results show that the simulator produces
dynamics that are consistent with previous versions of C-IMMSIM.
Additionally, the simulation extends those results by using AA
strings, adding a considerable quantity of information. This feature
precisely describes the added value of a tool of this kind.
The novelty and the power of our approach lie in the use of a
combination of two levels of description to study the immune
response by means of computer simulation. The first level is a
mesoscopic agent-based model representing cooperating cells that
mount an immune response. The second level is a set of molecular
binding prediction methods that are used to compute the binding
affinity of the molecules represented in the agent-based model.
The combination of these tools allows us to perform in silico
immunization experiments with specific real-world proteins and
could help to speed up drug design or clinically oriented research.
The system also provides a framework for testing various
prediction methods, because the two levels of description,
molecular interactions and cellular interactions, have purposefully
been kept separate in the computer code. This implies that a novel
method for predicting B cell epitopes could, for example, be easily
inserted into the simulator with minimal programming effort, and
the consequences could be immediately analyzed by looking at the
resulting immune dynamics.
Further work will focus on optimizing the procedures and
finding better algorithms for prediction of B cell epitopes. The
Miyazawa-Kernigan potential, which we have used to predict the
binding affinity between generic AA strings, can also be replaced
with a more accurate prediction method, should one become
available. The proposed architecture has been developed with
consideration for the issue of upgradability and modularity so that
new prediction methods can be easily inserted and used.
Figure 1. Simulation of an immunization experiment. B cell (panel a) and CD4z T cell (panel b) population during a typical immunization
experiment. An immunogenic molecule is injected at time zero and after six months. In both plots, the total number of lymphocytes along with the
immune memory compartment are shown. Panel (c) shows that the secondary response eliminates the antigen on a shorter timescale due to the
presence of memory cells ready to react.
doi:10.1371/journal.pone.0009862.g001
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To conclude, we believe this tool has the potential to ‘‘grow’’ by
acquiring precision, becoming a more and more useful prediction
tool in immunological research, in which in vivo or in vitro studies of
drugs and their effects on the immune response are too difficult or
expensive (either in terms of money or time) to carry out. For
example, it is possible to investigate why one particular epitope of
a given antigen is more immunogenic than another. Does the
uptake by the APCs determine this quality due to differences in
presentation on MHCs, or to differences in ligation through
immuno receptors? It is also possible to combine this kind of
analysis with simulations of different types of pathogenic behavior
and to study the cross-reactivity in the development of the flu
vaccine to select for the best combination of known viral peptides
to be used in order to achieve better protection. These are just a
few possible works that we are planning to pursue in the near
future.
Materials and Methods
At the molecular level, a key step for the simulation of the
immune response is the prediction of immunogenicity. Only the
immunogenic parts of an invading pathogen will trigger an
immune response in the affected host. Those parts are called
epitopes and are pathogen-dependent.
Molecular binding
In the specific context of the pathogen-induced immune
response, one distinguishes between B cell and T cell epitopes. B
cell epitopes are recognized by immunoglobulins, also known as
antibodies. The immunogenic parts are often located on the
surface of pathogenic proteins, because they have to be accessible
for binding. The epitopes mostly consist of discontinuous blocks of
the antigen sequence, i.e., sequence segments that are distantly
separated in the protein sequence and are brought into proximity
upon folding into tertiary or quaternary structures. The binding of
a B cell epitope to a B cell receptor (BCR, an immunoglobulin
covalently attached to the B cell surface) augmented by T helper
cell induction triggers the differentiation of naı¨ve B cells into
antibody-secreting plasma cells that make up the humoral immune
response. T cells can be divided into T helper cells (TH) and
cytotoxic T lymphocytes (CTL or TC). T helper cells act as
mediators between antigen presenting cells (APC) and plasma
cells, and, therefore, assume a central role in the immune
Figure 3. Immune response over 500 different simulations. Panel (a) shows the distribution of the time to clear the antigen in five hundred
simulations with different random seeds. Panels (b), (c), and (d) show that the immune effort calculated as the maximum number of cells (both CTLs,
CD4z T-cells) during the immune response, is higher for the homozygote type.
doi:10.1371/journal.pone.0009862.g003
Figure 2. The T helper lymphocyte count for the most
representative clones that are involved in the immune
response, e.g., those that are antigen-specific. In the inset of
the same panel, we plot the Simpson index.
doi:10.1371/journal.pone.0009862.g002
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response. CTLs kill infected host cells by means of cytotoxic
effector molecules that are released upon recognition of a complex
on the surface of the infected cells. The complex consists of an
epitope and an MHC class I molecule.
CTL epitopes are generated from cytosolic proteins. These
peptides result from the antigen processing pathway that involves
degradation by the proteasome, transport into the endoplasmic
reticulum via the transporter associated with antigen processing
(TAP), and presentation by MHC class I molecules. This
processing takes place in all cells containing a nucleus. The
MHC class II molecules, on the other hand, are produced only by
APCs, which include dendritic cells, macrophages, and B cells.
Epitope binding to MHC class II molecules are generated from
internalized proteins that are degraded in acidified endocytic
vesicles.
Prediction methods
The immune system recognizes pathogens by means of their
epitopes. As such, a protein belonging to a pathogen can be seen as
a collection of parts that are either epitopes or non-epitopes. The
binding strength of an epitope to a cell’s receptor is one of the
factors that determines the activation and strength of the immune
response. For the last several years, we have developed
computational methods that can predict T cell epitopes [3,4,6]
or B cell epitopes [66,67] in protein sequences. Although the
neural networks for MHC prediction, developed in [3,4,6], seem
to outperform other networks and methods [68,69], it should be
noted that these methods are not perfect. They cannot always
provide the same level of accuracy as experimentally-generated
data across all MHC alleles. Moreover, we assume that a peptide
bound on the surface of an MHC molecule always triggers the
immune system, which is not necessarily the case [70].
By implementing protein sequence-based representations for
both the host and the pathogen, we may obtain a patient-specific
genomic model capable of making specific predictions for different
host/antigen genotype combinations.
Until now, C-IMMSIM worked by using algorithms that represent
the biological complexity using bit strings. If protein sequences
rather than bit strings are used, different methods, such as Neural
Networks, are needed to predict binding. The switch from bits to
amino acids (AA) requires new algorithms to compute the affinity
among strings. Because C-IMMSIM is an agent-based model, every
agent (e.g., any cell), along with its interactions, is individually
simulated. This level of representation produces millions of
bindings in a typical simulation. For this reason, we developed a
new, fast Position Specific Scoring Matrix (PSSM)-based method, with
minimal sacrifices with respect to the prediction of performance.
To assess the predicting power of the matrices, a large set of
quantitative peptide MHC binding data were downloaded from
the IEDB database [71]. The dataset consists of 6,533 peptides
and covers 33 HLA- A and HLA-B human alleles. The PSSMs
were calculated as described above, using the original NetMHC-
pan method trained only on human data. None of the peptides in
the evaluation set were included in the training set. For each allele,
the predictive performance of the corresponding PSSM was
evaluated in terms of the Pearson’s correlation between the log-
transformed [72] IC50 value and the summed PSSM prediction
score. Although the NetMHCPan method almost systematically
outperforms the PSSM, the use of the latter in C-IMMSIM is
justified by the gain in computational speed.
The matrix method we employ has, on average, a Pearson’s
correlation coefficient of 0.56 with respect to experimental data,
whereas the original NN performance was 0.62 (see Table 1) [73].
One of the major requirements for the integration of the
prediction methods with an agent-based simulator is the
development of tools that calculate the stability of molecular
complexes.
Because there is no general method that can be used to predict
if, for example, a TCR will interact with any given MHC–peptide
complex, we have used the Miyazawa-Jernigan residue–residue
potential [74] to score the strength of the interaction.
In the following sections, we present the implementation and
combination of each of these processes. For a better understand-
ing, it is important to consider that each lymphocyte in the
simulation bears a receptor (called BCR for B cells, TCR
for both THs and CTLs), and APCs contain a definition of
HLA class I and II molecules with which they are equipped.
Moreover, interactions among cells can be either nonspecific (e.g.,
macrophages engulfing antigens) or specific. Specific interactions
must be accounted for when antibodies meet antigens or when
T-cells interact with other cells presenting foreign peptides on their
MHC.
An antigen is defined by a part or by the entire proteome, i.e., a
set of protein sequences imported via one or more FASTA files
(http://www.proteomecommons.org/data/fasta/fasta.jsp).
We make use of the following definitions. Let V be the
set of AA symbols, that is, V~fA,R,N,D,C,Q,E,G,H,I ,L,K,M,
F ,P,S,T ,W ,Y ,Vg. EVE~20 indicates the number of elements in
V. Let a~½a1,a2, . . . ,al(a) (where ai[V) represent a contiguous
stretch of AAs, where l(a) indicates the length of the sequence and
ak the k
th AA in the sequence.
In the following, we use p to indicate peptides, whereas we use
eB, eI , and eII to indicate epitopes for B cells, CTLs, and TH cells,
respectively.
Table 1. Comparison of the predictive performance of the
PSSM and NetMHCpan methods.
Allele N PSSM NetMHCpan
A0101 446 0.705 0.789
A0201 442 0.641 0.724
A0301 329 0.584 0.638
A1101 217 0.646 0.684
A2301 329 0.553 0.568
A2402 367 0.519 0.527
A2403 111 0.592 0.653
A2601 428 0.747 0.821
A2902 329 0.500 0.520
A3002 329 0.539 0.473
A3101 224 0.629 0.759
A3301 224 0.561 0.700
A6801 224 0.632 0.780
B0801 119 0.481 0.543
B1501 114 0.336 0.424
B3901 106 0.445 0.508
B4001 230 0.679 0.733
B5801 102 0.389 0.435
Average 6533 0.560 0.620
The columns give the allele name, number of peptide data points N , and the
performance of the PSSM and NetMHCpan methods, respectively.
doi:10.1371/journal.pone.0009862.t001
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Class I epitopes
Class I-type epitopes are linear sequences of 8 to 11 amino acids
that are processed from any protein of the pathogen via the
process described in section. Each MHC class I molecule, whose
total number surpasses the thousands of alleles to date [5], is
characterized by a specific binding motif that is possible to
‘‘decode’’. For the vast majority, the motif length is nine AAs long
(Figure 4). Class I T cell epitope prediction methods rely on
machine learning techniques. In previous work, we showed that
quantitative NNs, which had been trained to predict binding
versus non-binding peptides, are superior to the conventional NNs
[72]. Furthermore, quantitative NNs allow the straightforward
application of a query by committee (QBC) principle, in which
particularly information-rich peptides can be identified and
subsequently tested experimentally. Iterative training based on
QBC-selected peptides considerably increases the sensitivity
without compromising the efficiency of the predictions [75].
Because we want to handle generic proteins, the portions of a
protein that trigger an immune response must be identified. To this
purpose, we use the binding motif matrices generated from the NN
methods described in [5]. In short, we rank a set of one million
randomly selected natural peptides from the human genome using
the NN method; the top one percent of the peptides flagged as
binders are used to generate a binding motif, i.e., a 9 by 20 matrix.
The matrix is calculated using sequence weights, and is corrected for
low counts [4,76]. The average score of the low-scoring binders in
the top one percent is set as a threshold value for the matrix. This
threshold is then used to discriminate between epitopes and non
epitopes as follows.
The propensity is calculated as 2 log2 (P=Q), where P is the
probability of finding a given AA at a given position, and Q is the
probability of finding that AA in any protein in general. These
propensities are computed for each of the nine positions on a
potential epitope, and give the propensity for each of the 20 AAs.
Each matrix represents an approximation of the underlying NN,
but the matrix representation is computationally much faster than
the computation of the NN directly. Each row of the matrix
represents a position in the 9-mer, and the columns correspond to
the scores for that specific AA (an example is given in Table 2).
For a given 9-mer p~½a1,a2, . . . ,a9, ai[V, the sum of the
values at each position in the scoring matrix gives a score. That is,
let fBIi,ajg with i~1, . . . ,9 and aj[V,j~1, . . . ,EVE, be the matrix
of a specific class I MHC allele. The score of a generic 9-mer
peptide p is given by
~S(p)~
X9
i~1
BIi,ai
: ð1Þ
MHC class I peptide detection
We next describe how the scoring matrices for alleles are used in
the simulation. For an antigenic molecule Ag~½a1,a2, . . . ,al, (we
assume l§9), all possible peptides of the protein are found by
taking a sliding window of length 9, that is, all possible 9-mers are
fp1,p2, . . . ,pl{8g~f½a1, . . . ,a9,½a2, . . . ,a10, . . . ,½al{8, . . . ,alg:
For each 9-mer pk,k~1, . . . ,l{8, eq(1) computes the score of the
peptide ~S(pk). Of all possible 9-mers, those for which ~S(p)§H
BI
,
where H
BI
is the allele-specific threshold, are considered epitopes.
Hence, the epitope profile is
S^(p1),S^(p2), . . . ,S^(pl{8), Vi~1, . . . ,l{8,
S^(pi)~
~S(pi){H
BI
if ~S(pi)§H
BI
,
0 otherwise:
( ð2Þ
Note that 0ƒnƒl{8, that is, n can also be zero, meaning that
no epitopes are found in the antigen AA sequence. The threshold
HBI is computed as follows: for the set of peptides used to compute
the matrix for each allele, the matrix predictions for binding
affinity are calculated. Next, we extract the 1% strongest binders,
i.e., those with a high affinity for the MHC. Some of these 1%
have a lower binding affinity than others. We consider the 10
weakest binders of this subset to have a low-end binding affinity,
and we average these binding scores to get HBI . We assume that in
a random set of peptides, around 1% have a binding affinity below
500 nM for the MHC and are considered binders [72,77]. An
example is provided in Figure 4.
Class II epitopes
Class II-type epitopes are presented only on the surface of
APCs. For MHC class II epitope detection, we resort to the same
methodology used for class I. It is known that class II epitopes
have lengths that vary by up to 30 AA [78,79]. An analysis of all
known class II human binders from the EPIMHC database reveals
that the average class II epitope is 16 residues +4:2 in length
(note that the total number of epitopes found to bind human
MHCs was 2503 as of March 2008) [78]. Still, the binding core of
the peptides presented by the MHC can be reduced to a 9-mer
with flanking regions of variable length as demonstrated by
Nielsen [80]. This means that MHC class II epitope detection
can rely on the same principles as class I epitope detection. To
this end, in analogy to section, we created a set of matrices, BII,
able to score any given 9-mer for each allele covered by the NN
method.
Figure 4. Three-dimensional representation of an MHC class I
molecule (in green) complexed with a peptide (in red). The
structure has accession number 1OGA in the Protein Data Bank (www.
pbd.org).
doi:10.1371/journal.pone.0009862.g004
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MHC class II peptide prediction
Formally, we compute the score for each possible 9-mer
pk~½ak, . . . ,a8zk with k~1, . . . ,l{8 of the antigen AA string
Ag~½a1,a2, . . . ,al in a manner similar to that described in eq(1).
That is, we compute the epitope profile as
Vk~1, . . . ,l{8, S^(pk)~S^(½ak, . . . ,a8zk)~
X8
j~0
BIIkzj,akzj
:ð3Þ
Then, we compile the potential epitopes (meaning that they will be
checked for actual binding with the MHC class II), which are the
9-mers scoring above a certain threshold H
BII
,
Vk~1, . . . ,l{8, S(pk)~
S^(pk) if S^(pk)§H
BII
,
0 otherwise
(
ð4Þ
into a list of class II epitopes. We call these AA strings epitopes,
indicated by e1II , . . . ,e
n
II . Note that, once again, 0ƒnƒl{8.
The threshold H
BII
is computed in the same fashion as H
BI
.
MHC class II binding prediction is problematic. The 9-mers
form only the core of the binding peptide, the variability in alleles
is much wider than in class I alleles, and the available prediction
methods do not match the prediction capabilities of MHC class I
predictors [69]. To remedy these problems, we focused on a
limited set of MHC class II alleles for which good predictions exist,
and selected those available in the TEPITOPE method [81].
B cell epitope
The prediction of discontinuous B cell epitopes is still a major
challenge in vaccine design, and is difficult for two reasons: first,
available data on discontinuous epitopes in different antigens is
scarce compared to the available data on linear epitopes; second,
few antigens are completely annotated with respect to multiple
discontinuous epitopes in a single antigen. The presence of epitopes
that are not annotated in the data set increases the difficulties
associated with assessing the performance of prediction algorithms.
Due to these difficulties, the majority of prediction tools
available for B cell epitopes are based on linear prediction
methods. These are limited to continuous stretches of protein
sequences that may, in the end, be combined to form one or
several conformational epitopes.
Most tools available for the prediction of linear B cell epitopes
use propensity scale methods. These methods assign a propensity
value to each AA in the queried protein sequence based on
knowledge of the AAs physical and chemical properties. Propensity
scales have been developed based on antigenicity, hydrophilicity,
inverted hydrophobicity, accessibility, and secondary structure. As
part of the development of a new prediction method for linear B
cell epitopes, we tested all such scales for their ability to predict B
cell epitopes in an annotated data set taken from Pellequer et al.
[82]. It turns out that the propensity scales of Parker (based on
hydrophilicity) [83]. and Levitt (based on the secondary structure)
show better performance compared to other scales.
For the present work, we decided to use the Parker
hydrophilicity method rather than the BepiPred method because
the former is simpler and the performance gain using BepiPred is
marginal [66].
B cell epitope detection
The Parker propensity scale [83] is used to find B cell epitopes
in a generic antigenic sequence. The Parker propensity scale of AA
a[V is indicated by P(a)[R (see Table 3).
Table 2. Scoring matrix for allele A*0301.
Position 1 2 3 4 5 6 7 8 9
A 0.9 20.9 0.9 0.8 20.5 0.1 20.1 0.1 25.7
R 2.2 26.8 20.8 0.7 0.4 20.2 20.9 20.3 20.1
N 22.9 24.7 0.9 0.5 20.7 0.9 21.0 0.1 25.4
D 26.7 27.3 22.0 20.6 21.3 21.6 22.6 21.8 26.0
C 23.2 26.2 22.7 21.4 22.7 22.4 22.6 24.6 28.1
Q 21.6 0.3 21.5 0.6 0.5 0.4 21.4 20.4 24.0
E 25.5 26.7 23.1 20.1 20.2 21.2 22.8 0.3 24.5
G 20.1 25.6 21.2 20.5 21.2 20.8 20.3 20.6 26.8
H 0.2 27.1 20.8 20.2 20.2 0.1 21.4 20.2 23.5
I 1.0 2.3 20.4 21.2 20.4 0.5 0.4 21.0 27.5
L 0.0 3.0 1.0 20.8 20.3 0.4 1.4 0.6 27.3
K 2.5 26.1 0.0 0.8 0.5 20.8 21.3 0.1 7.4
M 1.1 3.1 1.6 20.5 0.5 20.2 1.2 21.8 26.4
F 21.8 23.4 2.4 0.3 0.3 0.4 1.5 1.3 26.6
P 25.6 27.1 24.2 0.3 0.5 0.6 20.1 1.0 26.2
S 0.9 1.2 0.8 1.2 1.2 1.3 1.6 0.7 25.4
T 20.3 2.3 22.2 0.1 0.3 0.2 0.4 0.2 25.9
W 27.1 27.1 0.6 20.6 0.9 20.2 0.9 20.4 26.6
Y 21.7 25.1 2.8 0.3 1.2 0.1 0.2 2.0 3.1
V 0.3 1.8 22.2 21.5 0.1 20.3 20.4 21.3 27.3
Ba,i is the matrix entry corresponding to i position (columns), a AA (row). Positive numbers indicate that the given AA is favored (often seen) at that position and
negative ones that it is not favorable (unlikely).
doi:10.1371/journal.pone.0009862.t002
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To calculate the propensity of an AA ak, we use the average of
the propensities of the AAs in a window ranging from position
k{3 to kz3. This smoothing window size has been shown to give
more accurate B cell epitope predictions [66] because B cell
epitopes are generally larger than a single AA. Let
Ag~½a1, . . . ,al be the antigenic sequence. We compute the
score with a smoothing window of seven AA, meaning that we
consider three residues on either side of the AA in question. We
then create a score profile for the sequence, S^k~S^(ak),
k~1, . . . ,l, as follows:
S^1~
1
4
(P(a1)zP(a2)zP(a3)zP(a4)),
S^2~
1
5
(P(a1)zP(a2)zP(a3)zP(a4)zP(a5)),
S^3~
1
6
(P(a1)zP(a2)zP(a3)zP(a4)zP(a5)zP(a6)),
S^j~
1
7
X3
k~{3
P(ajzk), j~4, . . . ,l{3,
S^l{2~
1
6
(P(al{5)zP(al{4)zP(al{3)zP(al{2)
zP(al{1)zP(al)),
S^l{1~
1
5
(P(al{4)zP(al{3)zP(al{2)zP(al{1)zP(al)),
S^l~
1
4
(P(al{3)zP(al{2)zP(al{1)zP(al)):
The profile is used to discriminate between residues that are likely
to be part of an epitope and those that are not. We use a minimum
score threshold Hparker
Vi~1, . . . ,l, Si~
S^i if S^i§Hparker,
0 otherwise,
(
where Hparker is 0.7. This value gives the best correlation between
predicted and real epitopes in the dataset used in [66]. Finally, we
label only contiguous regions of AAs, with profiles above the
threshold and lengths that are at least four, as possible B cell
epitopes. We call e1B, . . . ,e
n
B, 0ƒnƒl the B cell epitopes found.
Combined model
The simulation of the full sequence of system events, from
antigenic injection to the immune response, proceeds via antigen
recognition by lymphocyte receptors.
The contact potential of Miyazawa and Jernigan
There are no prediction tools available for describing specific
binding among BCRs, antigen epitopes, TCRs, and generic
MHC-peptides (both class I and class II). Therefore, we had to
define, in C-IMMSIM, a generic contact potential among AA
sequences to be used in those cases.
The work performed by Miyazawa and Jernigan on protein
energy potentials [84] provides us with a method for assessing
the chances of direct interactions among proteins in the
simulation. The protein–protein potential concept was derived
from the analysis of 3D structures in which the relative position
of AAs were determined. The contact potential matrix
estimated by Miyazawa and Jernigan reflects the entropy
between two residues. A low entropy means that the pair of
residues has low energy and, therefore, that interaction is
possible.
The contact potential defined between two AA strings is, thus,
based on the Miyazawa-Jernigan score. In the simulation, this
measure is used both when a BCR meets an antigen and when a
TCR meets an MHC-peptide complex. For the case of BCR, we
use a mean field approach, meaning that we assess the potential of
the whole BCR against the B cell epitope.
Let fMa,bg, with a,b[V, be the matrix found in [84]. If e1 is a
BCR and e2 is a B cell epitope, then we use the following formula:
M^(e1,e2)~
Xl(e1)
j~1
Xl(e2)
k~1
M
e1
j
,e2
k
: ð5Þ
For T-cell recognition, the procedure is different because it
requires the definition of a class of specific contact matrices CI and
CII for class I and class II, respectively.
We precomputed the contact matrices from known protein 3D
structures found in the Protein Data Bank (www.pdb.org) taking
residues that i) are within a distance of 5 A˚ and, ii) show contacts
between the MHC-epitope complex and the two chains (heavy
and light) of a bound TCR. The distance of 5 A˚ was selected
because most crystal structures with experimentally verified B cell
epitopes show that the residues on the antibody in contact with an
epitope lie within a 5 A˚ radius. We extend the use of this value to
the minimum distance needed between residues for molecular
interaction. By using the solved structures, it is possible to
Table 3. Parker’s propensity scale (from [83]).
a [ V R D E K S N Q G P T
P(a) 0.87 2.46 1.86 1.26 1.50 1.64 1.37 1.28 0.3 1.15
A H C M V I L Y F W
0.03 0.30 0.11 21.41 21.27 22.45 22.87 20.78 22.78 23.00
For each AA a[V, the propensity is indicated by P(a)[R.
doi:10.1371/journal.pone.0009862.t003
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determine which residues on a TCR bind to the MHC and
peptide, and which should be considered to be in the MHC–
peptide complex. The contact matrix derived for class I binding is
represented in Figure 5.
Therefore, if e1 is a TCR, e2 is a MHC-peptide complex, and
CI , CII are the contact matrices used for class I and class II
respectively, the binding affinity between the residues is
M^(e1,e2)~
Xl(e1)
j~1
Xl(e2)
k~1
(M
e1
j
,e2
k
:C
fI ;IIg
e1
j
,e2
k
): ð6Þ
Now, in order to determine effective thresholds for the
interaction strengths defined above, in eq(5) and eq(6), we
observed that, given two randomly chosen AA strings a[Vn and
b[Vm, (n and m also taken at random), the score M^(a,b) follows a
Gaussian distribution with average mM^~mM^ (n,m) and standard
deviation sM^~sM^ (n,m). Therefore, we pre-estimated those
values of m and s for a wide range of n and m, and we defined
the normalized score as follows:
M
0
(e1,e2)~
mM^{M^(e
1,e2)
sM^
:
(Note that M^ is negative.)
Next, we select those with a normalized score above threshold
HMJ as potential binders (i.e., positive probability), i.e.,
M(e1,e2)~
M ’(e1,e2) if M ’(e1,e2)§HMJ,
0 otherwise:
(
ð7Þ
The threshold value of HMJ determines the number of reactive
clones and was estimated to 0.075 so that in a typical
immunization experiment, antigen clearance is obtained in a time
frame of a few days. We use M(e1,e2) of eq(7) as the probability to
decide if e1 binds e2.
Putting all parts together: The simulation of immune
recognition
The simulation follows the same procedure as in the original bit-
string version [40], with the significant difference being that antigen
recognition and binding rely on the epitope prediction methods
described above. In the new model, we represent pathogens at the
protein level by their AA sequences, which means that we implicitly
account for only transcribed DNA. The host’s genotype is defined
by a set of four MHC class I and class II alleles.
The space volume is populated with an initial number of
entities. Lymphocytes are generated with a random AA receptor of
length 48 for BCRs and 32 for TCRs.
The sequence of events culminating in the immune response
(either humoral, cytotoxic, or both) is described in the following.
1. The Ag represented by one or more AA strings is injected;
N the B cell epitopes e1B, . . . ,enB are probed. Here we use the
method described in section;
N for each MHC of class I and II, the T-cell epitopes
S^(p1), . . . ,S^(pn) are found and scored (see section and
section);
2. Phagocytosis by antigen processing cells;
N Mw s and DCs perform unspecific phagocytosis of Ag;
N B cells must recognize, with their B cell receptor BCR, at
least one epitope of the Ag. Phagocytosis happens with a
probability p defined as follows:
– Given the precomputed B cell epitopes e1, . . . ,en, we
calculate, for a B cell receptor BCR, the score
S^(eiB)~M(BCR,e
i
B) by means of the MJ method, and
normalize those scores as described in eq(7) to get
S(e1B), . . . ,S(e
n
B).
Finally, the probability that a B cell will recognize
at least one of the epitopes is calculated as
p~1{Pni~1 (1{S(e
i
B)), that is, the probability for the
BCR to match at least one epitope of the antigen;
3. Antigen digestion by APCs. Once an APC (Mw, DC, and B
cell) has internalized the antigen, it is processed as follows:
N Because the epitopes e1II , . . . ,enII have been determined as
described in section, we can randomly select. This selection
is performed by means of the random wheel selection procedure:
draw a number u between 0 and 1 with a uniform
probability distribution and select r if S(er{1II )ƒuvS(erII ).
One epitope erII , with a probability that is given by the
normalized score S(erII );
Figure 5. The contact matrix used for class I presentation and
TCR binding. Labels on the axis represent positions on the peptide-
MHC complex that are in contact with the TCR chains a and b. The
matrix was derived using the structure indexed under the reference
1OGA in the PDB database. Labels on the columns report the position
indices for the residues in the two TCR chains as they are numbered in
the PDB file (chains E and D respectively). Rows: Labels report the
position indices for the MHC residues and the peptide (chains A and C,
respectively, in the structure file). A blue dot means that the pair of
residues in the row/column are within 5 A˚ distance, and are considered
to be in contact. Otherwise, they are not. In the program, this matrix is
coded with ones (blue dot) and zeros (no dot).
doi:10.1371/journal.pone.0009862.g005
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N Analogously to the endocytotic digestion, endogenous
digestion takes place in cells that are infected by a virus. In
this case, the epitopes e1I , . . . ,e
m
I are found by using the
method described in section;
Building the MHCI-peptide sequence: each infected
cell bears a set of two A and two B alleles.
This implies that each protein from the pathogen is processed
at most four times during the discovery process for class I
epitopes. After processing the antigen protein, each cell
presents, on its surface, one randomly chosen epitope with a
probability that is proportional to the score of that epitope
divided by the sum of scores of all found epitopes. This choice
reflects the competition for MHC molecules among the
protein fragments produced by the proteasome. Inside a single
infected cell, antigen peptides are processed so that they bind
one MHC class I molecule. Because we allow cells to display
only one MHC peptide molecule per time step on their
surface, we have to choose the display protein from within the
haplotype (i.e., the four available, two A- and two B- alleles).
This is performed by random selection at each time step. The
procedure computes the epitope profile S^(e1I ), . . . ,S^(e
l{8
I ) as
described in eq(2), then normalizes it as follows:
Vi~1, . . . ,l{8 S(eiI )~
S^(eiI )Pl{8
j~1 S^(e
j
I )
: ð8Þ
The normalized profile is used to select, from the probability
distribution S(eiI ), the epitope e
r
I to be presented on the
surface of the cell.
This complex is then used to compute the matching score
against the cytotoxic T cell receptor (see section).
4. The APC shows the MHCIIpep (the complex formed by an
MHC class II and a nine AA-long peptide) on its surface for
TH-TCR recognition. This recognition makes use of the score
defined in eq(7);
5. Humoral response
N Stimulated B cells start cloning and differentiating into long-
lived memory cells and antibody-producing plasma cells;
N Plasma cells secrete antibodies;
N Antibodies bind antigens’ epitopes;
– to compute the affinity between antibodies and the
antigen, we follow the same procedure as the one applied
for antigen recognition by B cells, (section and section);
– an immunocomplex is formed by the combination of an
antibody and an antigen;
6. Cytotoxic response;
N For infected cells showing MHCIpep (a complex formed by
an MHC class I and a 9-mer) on their surface, recognition of
CTLs via their TRC is performed using the Miyazawa-
Jernigan potential between the MHCIpep and the TCR.
The normalized score (eq(7) in section) is used as the
probability of binding;
N Upon successful recognition (i.e., binding), cytotoxic cells kill
virus-bearing cells and start cloning.
Thymus education of T lymphocytes
As mentioned, we filter randomly created T cell receptors by
means of a procedure that mimics the positive and negative
selection of immature thymocytes in the thymus gland. This
reflects the clonal deletion theory proposed by Burnet, according to
which self-reactive lymphoid cells are destroyed during the
development of the immune system to prevent autoimmunity.
In C-IMMSIM, the thymus is modeled as a two-layer filter (see
Figure 6), and the same procedure for detecting antigen peptides is
used to differentiate self peptides from proteins that represent the
self. This process allows T-cells to develop self tolerance (in the
negative selection) while eliminating useless cells (positive selec-
tion). The self is defined by specifying a random set of naturally
occurring 9-mers extracted from the human proteome. These
peptides are the same as those that have been used to compute the
matrices for the different MHC molecules.
In practice, we allow a T cell to enter circulation (i.e., to reach a
secondary organ as a mature thymocyte) with a probability given
by the product of the probability of being positively selected and
the probability of being negatively selected,
Pr(TCR is selected)~Prz:Pr{, ð9Þ
with
Prz~1{P
nmhc
j~1
(1{M(TCR,MHCpep)), ð10Þ
where M(:,:) is the Miyazawa-Jernigan contact potential calcu-
lated as in eq(7), the only difference being that residues in contact
with the MHC and the TCR are taken into account, because there
is no peptide attached to the MHC at this stage.
Negative selection is performed according to the following
procedure: for each MHCj (j~1, . . . ,nmhc) and for each self AA
string selfk (k~1, . . . ,nself ),
N compute the sequence profile of the selfk with respect to the
MHCj , as described in section and section, according to
whether the T is a helper or a cytotoxic T cell;
N randomly choose a peptide and create an MHCpep string;
N compute the Miyazawa-Jernigan contact potential
M(TCR,MHCpep).
Finally, the probability that a T cell survives negative selection is
Pr{~ P
j,k
(1{M(TCR,MHCpep))
 ThymEff
, ð11Þ
where the MHC molecule is composed of MHCj and the chosen
peptide of the selfk. The exponent ThymEff is required because
we treat the thymus as if it were composed of ThymEff sub-layers
(by simulating multiple encounters with each thymic cell receptor).
Parameters of the model
The simulator accepts, as input, the definition of the antigen AA
sequence (in the form of a FASTA file), the matrices defining the
binding motifs for the haplotype (four matrices for class I, two
HLA-A and two HLA-B, as well as two matrices for class II, as
explained in section and section), and other variables that are in
part derived from the literature and in part are free parameters
used to tune the system. Most of the parameters of this version of
C-IMMSIM are the same with respect to the previous bit-string
version. The parameters are described in http://www.iac.cnr.it/
filippo/parameter-page.html. The main difference consists in the
fact that, now, all clonotypic receptors, peptides, and epitopes are
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Figure 7. The overall architecture of the simulation tool. The definition of HLAs is given by means of the precomputed matrices, as described
in sections and. Moreover, we select the pathogen as a collection of peptides from a database of FASTA files. The output of the simulator consists of a
set of ASCII or binary files describing the state of the system at each time step. From the files, various statistics can be extracted.
doi:10.1371/journal.pone.0009862.g007
Figure 6. The two-layer filter realized by the thymus to eliminate auto-reactive T lymphocytes. T-cells develop self tolerance during
negative selection, whereas they are eliminated as useless during positive selection.
doi:10.1371/journal.pone.0009862.g006
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represented by strings of AAs. Moreover, the definition of the
HLAs is now given in terms of affinity matrices rather than in bit-
strings..
In the following experiments the self is given as a random set of
naturally occurring 9-mers extracted from the human proteome.
Since we are not focusing on studying th emergence of
autoimmunity diseases, we arbitrarily take nself = 50 and Thy-
mEff = 5.
As output, the simulator produces a set of files corresponding to
population data (both total number of lymphocytes and the
division between clonotypes, cytokines, and antibody concentra-
tions per lattice point) plus Logo files [85] of lymphocytes at
certain time steps.
The overall architecture is depicted in Figure 7.
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